```
IN THE CIRCUIT COURT OF THE STATE OF OREGON
        FOR THE COUNTY OF MULTNOMAH
 2
 3 The Estate of JESSE D. )
   WILLIAMS, Deceased, by and )
4 through MAYOLA WILLIAMS, )
Personal Representative, ) Volume 5-B
          Plaintiff,
 6
                               )
                                   No. 9705-03957
                               )
          vs.
7
   PHILIP MORRIS INCORPORATED, ) Afternoon Session
8
          Defendant.
                               )
9
10
               TRANSCRIPT OF PROCEEDINGS
11
          BE IT REMEMBERED that the above-entitled
12 Court and cause came on regularly for hearing
13 before the Honorable Anna J. Brown on Friday, the
14 26th day of February, 1999, at the Multnomah County
15 Courthouse, Portland, Oregon.
16
                      APPEARANCES
17
             Raymond Thomas, James Coon,
             William Gaylord and Charles Tauman,
18
             Attorneys at Law,
19
            Appearing on behalf of the Plaintiff;
             James Dumas, Billy Randles, Walt Cofer
20
             and Pat Sirridge,
21
             Attorneys at Law,
             Appearing on behalf of the Defendant.
22
              KATIE BRADFORD, CSR 90-0148
23
                 Official Court Reporter
24
            226 Multnomah County Courthouse
                 Portland, Oregon 97204
25
                     (503) 248-3549
```

(Friday, February 26, 1999, 1:35 p.m.) 1 2 PROCEEDINGS 3 Afternoon Session 4 (Whereupon, the following 5 proceedings were held in 6 open court, out of the 7 presence of the jury:) 8 THE COURT: All right. I would like to 9 into on the record to take up a request from The 10 Oregonian. I understand that we have staff 11 photographer, Steve Nehl, N-e-h-l, in court. 12 And I have a letter from Randy Rassmusen (ph), 13 Deputy Photo Director at The Oregonian. 14 It reads, "Please accept this letter as 15 request for public access coverage in the trial of Williams versus Philip Morris, Inc., in the 16 17 courtroom of Judge Anna Brown. We would like to 18 take still photographs during the court 19 proceedings as provided for in Uniform Trial 20 Court Rule 3.180." 21 Mr. Nehl, I am refreshing my memory on the provisions of the rules as they apply to 22 23 still cameras. I have not had experience were a 24 still photographer in the courtroom during 25 proceedings. I have used video cameras.

So maybe you can first tell me whether you have had that experience; and, if so, what approach you would take in order to comply with the rule.

1 2

MR. NEHL: Basically, I have done quite a bit of court photography. I would standing probably back here. The rules are that no jury photographs are to be taken, and just be photographing the court proceedings, individuals during the court proceeding from the back, no flash, and I have a camera that has a case that kind of goes around it to make it quieter, and I have never had a problem.

THE COURT: Do you have it here so that I can hear what it sounds like?

MR. NEHL: It is downstairs. I didn't know I would be able to speak to you directly at this point.

THE COURT: I am going to need to hear what it sounds like before I can make a decision, so if it is important for you to have that decision made before this afternoon's proceeding, you might as well go get it.

One of my concerns is that whatever media access we have, obviously comply with the rule,

and that requires that it happen without notice, 1 2 and the degree of sound is of concern to me. 3 MR. NEHL: Okay. I'll be right back. THE COURT: Thank you. 4 5 (Pause in proceedings.) THE COURT: First, I'm trying to figure 6 out where you might be stationed, what it is you 7 8 might be viewing. Wherever it is, it would have 9 to be in one place and one place only. 10 MR. NEHL: Either here or over in that 11 area. 12 THE COURT: What would you intend to be 13 photographing? 14 MR. NEHL: Like questioning the witness 15 probably and counsel. 16 THE COURT: The rule says you may not 17 cover recesses of a court proceeding, 18 proceedings in chambers? 19 MR. NEHL: Uh-huh. THE COURT: Conferences involving counsel 20 21 and the judge at the bench, conferences 22 involving counsel and their clients, which is to 23 say almost any view the parties at the table if 24 they are conferring with their lawyers would be 25 off limits. And those proceedings in this jury

trial from which the jury is excluded, so every 1 2 time the jury is out of the room. 3 MR. NEHL: Uh-huh. THE COURT: So your proposal would be to 4 5 stand, for example, where you are now? MR. NEHL: Either here or over by the 6 7 coats. 8 THE COURT: Just so you know, there has 9 been action going on out here which would be 10 directly in your line of sight in you were 11 standing in that corner, and the witness is, of 12 course, here. 13 MR. NEHL: This would be better for me. 14 THE COURT: Why don't you give us an 15 example of what this mind sound like as you use 16 your equipment. Go ahead. And how often to you 17 expect you would be making those sounds? 18 MR. NEHL: It would certainly not be 19 continuous. It would be intermittent at best. THE COURT: Anything for the record from 20 21 plaintiff? Any inquiry of Mr. Nehl or any 22 statement for the record? 23 MR. GAYLORD: Dr. Benowitz -- I asked 24 Dr. Benowitz, and I don't think he has any 25 objection particularly. The only thing I would

say is that it just strikes me that both attorneys and witnesses might be better served by not having the sound of the camera going off right in the middle of either a question or an answer.

1 2

THE COURT: Mr. Nehl, would you with be willing to not take a photograph in the middle of someone's thought processes as they're expressing a question or expressing an answer?

MR. NEHL: When would I be photographing then, I guess is the question?

THE COURT: For example, someone is asking a question, in the middle of the sentence, they're formulating a thought, the click, click, click could be distracting to counsel. The witness could be in the middle of answering a question and finishing a thought, and click, click, click could be distracting to the witness.

However, at the end of every question there is a pause and end of every answer there is a pause, and that wouldn't be distracting is what I thing is being proposed?

MR. NEHL: It would be better for me if I was photographing during an actual exchange, I

think, but if that is unacceptable.

1 2

THE COURT: Well, I can hear the shutters from up here. I can hear your clicking from up here. And I can appreciate that if I am in the middle -- if I were the questioner and I was in the middle of a particular question and trying to keep my train of thought uninterrupted, that could be disruptive.

The same is true for the witness who in fairness needs to be able to concentrate on answering the question, it just seems to me that no one of those delays is going to be more than a matter of seconds.

MR. NEHL: What I have found, though, is when you are listening for the camera as we just did here, you're listening for the sound, where if there is any kind of sound in the courtroom, like, for instance, people talking, you can't really -- it is not really evident.

THE COURT: How about this: How about we try it, and if -- I am not getting to a place, I am suggesting to counsel in response to your concern, Mr. Gaylord, that we see if the shooting that the reporter chooses to make does, in fact, interfere with a questioner's process

1 or a witness' answer. MR. GAYLORD: I suppose it's my concern 3 because it occurred to me. I think Your Honor 4 can take care of it. 5 THE COURT: Any other concern on behalf 6 of the plaintiffs? 7 MR. GAYLORD: None, Your Honor. 8 THE COURT: For the defense? 9 MR. GAYLORD: No objection. 10 THE COURT: Mr. Nehl, you're welcome to 11 stand right where you are. 12 MR. NEHL: Can I sit down? THE COURT: Sure. Would you make room 13 14 for him? 15 Doctor, come on back. 16 MR. COFER: We do have one matter, Your 17 Honor. What I believe I did just before the break was lay a predicate to use this book as a 18 19 learned treatise and ask the doctor about the 20 comments in it and posed a question based on a 21 learned treatise. 22 MR. GAYLORD: May I speak to it, 23 Your Honor? 24 THE COURT: Well, you really shouldn't. 25 Mr. Thomas is on point for this witness and he

should be the one who addresses if plaintiff has an objection to the proffer that the defense contends they made adequate to use the book as a learned treatise.

MR. THOMAS: Does the defendant object?
THE COURT: No. The defendant is putting
you on notice that they contend they've laid an
adequate foundation and they want to now impeach
as though that document, that book, is a learned
treatise. They are giving you an opportunity to
object now and resolve it before the jury comes
in.

MR. THOMAS: I don't believe that he said that this was an authoritative document in the area, but that it would be something, that while it does not rise to the level of peer review, it would be something that he would look at, but it would not be something that he would necessarily rely upon.

THE COURT: I don't believe an adequate foundation was laid. The witness testified that he would consider this matter in doing his normal work, but the predicate has to be established that the material is in fact authoritative or was relied upon by the witness

```
in forming his opinion, and that foundation was
 1
 2
       not laid. The objection is sustained.
 3
             Anything else before we bring in the
 4
       jury? All right. Let's get them.
 5
                             (Whereupon, the following
 6
                            proceedings were held in
 7
                            open court, the jury being
 8
                            present:)
 9
             THE COURT: Good afternoon, jurors,
10
       welcome back.
11
             Mr. Gaylord.
12
             MR. GAYLORD: Your Honor, I would just
13
       like to introduce Joanne Williams Branch.
14
             THE COURT: Jurors, Ms. Branch is the
15
       daughter of Mayola and Jesse Williams. She is
16
       here in her mother's place this afternoon.
17
             Now, continuing with the
18
       cross-examination.
19
             MR. COFER: Thank you, Your Honor.
20
21
22
23
24
25
```

NEAL BENOWITZ 2 Was thereupon called as a witness on behalf of the 3 Plaintiff and, having been first duly sworn, was

4 examined and testified as follows:

5 6

FURTHER CROSS-EXAMINATION

- 8 BY MR. COFER:
- 9 Q. I have one more question about the book 10 we were discussing before we broke, but, first, 11 before we get to that, we talked some this morning 12 about the tar and nicotine levels declining 70 13 percent from the 1950s to the 1990s. Do you 14 recall that?
  - A. Yes.
- 15 16 Q. I think we basically made clear what our 17 positions were. What I want to point out is the 18 source of that information. And you're aware, of course, aren't you, that that data is published in 19 20 the 1989 Surgeon General's Report, "25 Years of 21 Progress." Correct, Doctor?
- 22 A. Yes.
- 23 Q. Here I'll just briefly show the chart.
- 24 And of course, you are familiar with this
- 25 document, right?

- N. Benowitz X
- A. Yes.
- Q. And it shows how tar levels have dropped at the top, and nicotine levels have dropped at the bottom, correct?
- 5 A. Right. As long as it's clear what you 6 mean by tar and nicotine levels. They are by 7 smoking machine testing.
  - Q. Yields, FTC methods, correct?
- 9 A. Yes.

- 10 Q. You're familiar with Deitrich Hoffman and 11 Klaus Broodermen (ph)?
- 12 A. Yes.
- 13 Q. Doctors Hoffman and Broodermen are 14 affiliated with the American Health Foundation, 15 correct?
- 16 A. That's correct.
- 17 Q. The American Health Foundation's senior 18 researcher is Dr. Ernst Wynder, right?
- 19 A. Right.
- Q. Dr. Ernst Wynder is one of the pioneers of smoking and health, right?
- 22 A. Yes.
- Q. He was Ernst Wynder of the famous
- 24 Wynder-Graham mouse skin painting studies,
- 25 correct?

- N. Benowitz X
- A. Yes.

4

8

11

- Q. And you do recognize Drs. Hoffman and Broodermen as authorities in the field, right?
  - A. Yes.
- 5 Q. Particularly of changes in cigarette 6 design and composition over time and how they 7 influence yield smoke constituits, correct?
  - A. Yes.
- 9 Q. And you are familiar with the Journal of 10 Smoking-Related Disorders, correct, Doctor?
  - A. Yes.
  - Q. And that's a reliable journal?
- 13 A. Yes. Although that journal is actually 14 no longer published.
- Q. Okay. But the fact is -- and let me just show you the article. Can you see it on the monitor? It's entitled, "Changes in cigarette design and composition over time and how it yields smoke constituits," by Drs. Hoffman, Broodermen and a third researcher, I can't pronounce his name?
- 22 A. Yes, I see it.
- Q. And in it they also state that, "Measured on the basis of standardized," your point,
- 25 "machine smoking conditions, the sales weight of

#### 14 N. Benowitz - X 1 average tar and nicotine deliveries in the smoke 2 of U.S. cigarettes had decreased from 38 3 milligrams and 2.7 milligrams in 1954 to 12 milligrams and .95 milligrams in 1993, which is right around 65 to 68 percent. Do you accept my 6 math? 7 Α. Yes. 8 THE COURT: Would you slow the pace just 9 a bit? 10 BY MR. COFER: 11 Q. One last thing on this book. Yesterday you were shown Plaintiff's Exhibit 81, and this 12 13 was the Bird I study of the quit smoking campaign in Greenfield, Iowa, in conjunction with the 14 15 movie. Do you recall that, Doctor? 16 A. Yes. 17 Q. Mr. Thomas pointed out the cover page, 18 and it says, "This report contains confidential 19 information which is confidential to the business of the company. The information must be carefully 20

handled and not divulged to the outside sources 22 without express authorization." Did I read that

25 but it does sound like the quote that was read

A. Yes. Well, I can't see the bottom part,

21

24

23 correctly?

N. Benowitz - X 1 yesterday. Q. And also its says, "Confidential," on it. 3 Do you remember that? 4 Yes. Α. In this book, Chapter 16, Cold Turkey in 5 Q. Greenfield, Iowa, follow-up study, Frank Ryan, 6 7 same study, correct? 8 A. I believe so. 9 All right. Thank you. Q. 10 We've had quite a bit of testimony about the documents from Bill Dunn, haven't we, Doctor? 11 12 A. Yes. 13 Q. And in fact, we pointed out that Bill 14 Dunn's nickname was the nicotine kid, right? 15 A. Yes. 16 Q. Clearly, from Dr. Dunn's documents, he believed nicotine played an important role in why 17 18 people smoke, correct? 19 Α. Yes. 20 And judging from his documents, he Q. 21 expressed that view pretty freely and fairly 22 colorfully. Would you agree with that? 23 A. Yes.

Q. Are you aware, Doctor, that there were

25 others at Philip Morris at the same time who

3

5

6 7

8

9

10 11

12

1 disagreed with Dr. Dunn about the role of nicotine 2 in smoking?

- A. I don't recall specifically who those people were, but there may well be.
- Q. Let me just show you a couple of examples. This is Defendant's 630 from Wakeham to Seligman.

First paragraph, "The program reviewed by Dr. Dunn on smoking behavior once again prompts me to express the opinion that the total emphasize of our research on the psychopharmacology of nicotine is wrong.

13 "I do not deny that many smokers maintain 14 the habit for psychopharmacological reasons but 15 other factors must come into play. To ignore them 16 almost completely, as the present program does, is 17 a mistake we have made too long. As a 18 consequence, for example, the industry is facing a 19 dearth of good, basic information which will 20 support the positive aspects of cigarette 21 smoking."

And the last paragraph on this page, "The often-repeated marketing concept that smokers smoke for favor is surely not entirely a figment of marketing imagination. Too many smokers

express taste preferences for it to be an insincere gesture. Flavor must be one of the motivating factors, so how can it all be nicotine when there are many other flavor contributors."

The point is even Dr. Wakeham recognizes that nicotine plays an important role, but says there are other things, too, right?

A. Yes. I am sure that Dr. Dunn would -just as I did in my testimony, talked about other
factors that interact with nicotine in smoking
behavior.

MR. COFER: Okay. Let's look at Fagan to Seligman. Same time period. This is Exhibit 631, counsel.

# 15 BY MR. COFER:

Q. "Dr. Dunn has set his prime goal, the solution of the problem of what it is that keeps a smoker smoking. This is a laudable objective in trying to answer an intriguing question.

trying to answer an intriguing question.

"It seems, however, that he has prejudged
the issue and has decided that the answer is the
psychophysiological effects of nicotine. The
major effort of this group is to find evidence to
substantiate this single hypothesis. This is much
too narrow an approach.

"It supposes that all smokers at all 2 times seeks the effects of nicotine. I submit that there are other reasons people smoke. The situational smoker to name -- only at parties, 5 only at work, to name only one other, Dr. Daniel Horne and Dr. McKinnal (ph) have developed the 6 7 pathology of smokers.

"Horne has four classes; McKinnal has a 9 dozen classes. Each class is smoking presumably for different reasons. Although it may be that nicotine is the underlining stimulus, it seems unlikely that it could account for all the differences. Again, recognizes that nicotine is important, but also recognizing there are other things, other things that should be researched," correct?

> Α. Yes.

And finally, here is one, this is not an Q. exhibit, not substantive evidence. I am using it as impeachment.

21 MR. THOMAS: We have a problem. May we 22 approach the Court?

23 THE COURT: Let's handle this in 24 chambers.

25

8

10 11

12

13

14

15

16

17

18

1 (In chambers:) 2 MR. THOMAS: My understanding is what 3 counsel just said is this is impeach. And that 4 it was said this is not an exhibit off of the exhibit list. I haven't seen it before and I 5 don't see how this is impeachment of 6 7 Dr. Benowitz, (a); and (b) to the extent that it 8 is evidence that it was said is not relevant. 9 MR. COFER: I'll hand the Court the 10 highlighted portion. What it is, it's a Philip 11 Morris document. It was not on the exhibit 12 list. I pulled it off the internet and it shows 13 that there is a debate within the company at the 14 applicable time about whether nicotine is the 15 reason people smoked, and people smoke and 16 nicotine isn't the reason. 17 Just again to show the date and show 18 evidence that when Dr. Benowitz testified 19 yesterday that for Philip Morris the ticket was 20 nicotine, period, end of paragraph, that is not correct. There were others who had different 21 22 views. 23 THE COURT: Was this designated as an 24 exhibit? 25 MR. COFER: To be honest, I did not

anticipate needing to impeach him with that testimony.

THE COURT: That last comment, I am having trouble with. This is a witness well known who your client as someone who takes the position, that Philip Morris takes Position A in the public and Position B in the private. This isn't a new approach from the witness, is it?

MR. COFER: I don't think it -- I didn't know who the witness was because the witness wasn't disclosed. We pulled documents in anticipation of a variety of witnesses. There are public held witnesses who cover a bunch of different territory, depending on who else is coming. I missed that document. It is germane. I want to use it to transition into another topic.

THE COURT: I am sustaining the objection. I think it is an exhibit that is substantive and applicable and should have been disclosed if you're going to use the document. The subject matter is fair game.

MR. COFER: Thank you.

1 2

21 N. Benowitz - X 1 (Whereupon, the following proceedings were held in 3 open court, the jury being 4 present:) 5 THE COURT: Go ahead. 6 MR. COFER: Thank you, Your Honor. 7 BY MR. COFER: 8 Q. Dr. Benowitz, you're aware, are you not, 9 that within Philip Morris there were really opposing views about the importance of nicotine? 10 11 A. I am not sure if there were opposing 12 views about the importance of nicotine, but rather 13 whether there were also other things that were 14 important. 15 Q. Okay. Let me clarify it a little. The 16 first view is that nicotine is the primary reason 17 people smoke, and without a certain level of nicotine, smokers will quit. You are familiar 18 19 with that view, are you not? 20

- A. Yes.
- 21 Q. In addition, there was a view that really 22 people smoked primarily out of habit and for taste 23 and that removal of nicotine really would not have 24 a big effect on the habit, that people may well 25 smoke without nicotine. Are you aware of that?

- 1 A. I -- no. I don't doubt that that may not 2 have existed, but I have never read that.
- Q. Okay. Well, yesterday, and I think even today, you made the point that, in your view, people don't smoke without nicotine, right?
  - A. Yes.

6

10

- 7 Q. That basically cigarettes without 8 nicotine would noting be successful in the 9 marketplace?
  - A. Right.
- 12 Q. Now, the fact is Philip Morris actually 12 introduced a cigarette without nicotine into the 13 market, right?
- 14 It was a product called Next, N-e-x-t.
  15 And what Philip Morris did was they used
  16 technology that is used for taking caffeine out of
  17 coffee, and they were able to extract basically
  18 all the nicotine from cigarettes, correct?
  - A. Yes.
- Q. And they spent a bunch of money and a bunch of time and a bunch of effort coming up with that product, correct, Doctor?
- 23 A. Probably.
- Q. Would it surprise you to learn that they spent 300 million dollars trying to develop a

- N. Benowitz X
  1 denicotized cigarette?
- 2 A. I wouldn't know how to guess at that. If 3 you tell me that, I believe it.
- Q. Okay. And the fact is they did bring it to market, right?
- 6 A. Yes.
- 7 Q. People didn't buy it, right?
- 8 A. Yes.
- 9 Q. And people reported that it tasted bad,
- 10 right?
- 11 A. Yes.
- 12 Q. All right. Let's talk about some of the
- $\,$  13  $\,$  words that Mr. Thomas wrote on the board, and
- 14 let's start with psychoactive. You would agree
- with me, would you not, that psychoactive does not mean addiction?
- 17 A. Yes.
- 18 Q. There are many things that have 19 psychoactive effects?
- 20 A. Yes.
- 21 Q. There are common substances we use every
- 22 day that has affects on brain receptors?
- 23 A. Yes.
- Q. Sugar?
- 25 A. Not directly on receptors by the sugar

- 1 molecule, but it can have some psychoactivity.
  - How about milk? Ο.
- 3 Α. Milk also is -- has got tryptophan which is a precursor to serotonin. It doesn't have a 5 direct effect on the receptors, but can have behavioral effects. 6
- Q. Tell the jury how that works, how the tryptophan in the milk affects the serotonin and 8 9 how it affects the brain?
- 10 A. Well, tryptophan is a precursor. It is 11 made into serotonin.
- 12 Q. Right. And this produces the effect, 13 sometimes milk will make you drowsy or slightly 14 sleepy?
- 15 Α. Yes.

- 16 Q. Why you drink more milk if you want to go 17 to sleep?
- 18 Yes. Α.
- There is a substance in chocolate called 19 Q. 20 theobromine; is that correct?
- 21 A. Yes.
- 22 Is theobromine a receptor blocker? Q.
- 23 A. Yes.
- 24 Q. What does that mean?
- 25 A. Well, some drugs work by combining with

- the receptor and doing the same thing as one of the body's own hormones do. And other things, like theobromine, block a substance, adenosine, which normally is the substance in the body that has the effects. What theobromine does is block 6 the adenosine effects.
- Now, caffeine, we talked about caffeine 8 yesterday with Mr. Thomas. Caffeine is a receptor 9 blocker, too, isn't it?
  - Yes. Α.

7

10

11

12

13

14

19

20

- Now, the other thing we talked about, you Q. may even have made a drawing, is that nicotine causes the brain to grow more receptors, correct?
  - A. Yes.
- 15 Q. Caffeine causes the brain to grow more 16 receptors, doesn't it?
- 17 A. Yes. Not the same time kind, they're different kinds of receptors. 18
  - Q. But even though they're not the same type, caffeine changes the brain, causes it to grow more receptors, right?
- 22 A. Sort of. Your overall idea is right. It 23 has to do with expression and it's technical, but, 24 in general, what you say is correct.
- 25 Q. Okay. Reinforcing. Would you agree with

- 1 me that if something is reinforcing, that is not
  - the same thing as saying it's addictive?
- 3 A. Yes.
- 4 Q. Lots of things are reinforcing?
- 5 A. Yes.
- 6 Q. Food?
- 7 A. Yes.
- 8 Q. Water?
- 9 A. Yes.
- 10 Q. Sex?
- 11 A. Yes.
- 12 Q. Saccharin?
- 13 A. Can be.
- 14 Q. Pain?
- 15 A. I suppose. It is not one of the things 16 that you usually think about as a reinforcer. It
- 17 is a negative reinforcer for most people.
- 18 Q. EEG brain waves. Lots of things cause
- 19 EEG brain waves?
- 20 A. You mean changes in EEG brain waves.
- Q. Right.
- 22 A. Yes.
- Q. Music?
- 24 A. It can.
- Q. Exercise?

- N. Benowitz X
- A. Yes.
- 2 Q. Sugar, caffeine?
- A. Probably. I know caffeine can. I am not sure about sugar.
- 5 Q. Okay. Let's talk a little about
- 6 nicotine. Nicotine occurs naturally in the
- 7 tobacco plant, right?
  - A. Yes.
- 9 Q. Anyone who want to research nicotine can
- 10 do it by taking a tobacco plant?
- 11 A. They could.
- 12 Q. You don't have to work at a tobacco
- 13 company, correct?
- 14 A. Correct.
- 15 Q. The nicotine is available and can be
- 16 studied, right?
- 17 A. Yes.
- 18 Q. And in fact, nicotine had been studied
- 19 outside of tobacco companies for a long time?
- 20 A. Yes.
- 21 Q. Thousands of articles since the early
- 22 '60s?

- 23 A. Yes.
- Q. Now, it was known before the Surgeon
- 25 General's Report was published in 1964, that

#### 28 N. Benowitz - X 1 nicotine was psycho activity wasn't it? 3 MR. THOMAS: Objection, foundation, known 4 by who? 5 BY MR. COFER: 6 Q. Known outside the tobacco companies, 7 correct? 8 A. It was known by scientists, yes. 9 Known by independent scientists and Ο. 10 medical authorities? 11 Yes. Α. 12 Q. People whose job it was to look into the 13 issue? 14 A. Probably, if there were such people. I 15 am not sure what people you're talking about. 16 Q. Were there public health people before 17 '64? 18 Yes. I am not sure at what point in time 19 the public health people prior to '64 started to 20 get interested in smoking. I guess, it was the

21 early '60s when it began.
22 Q. Well, the evidence -- not the evidence,
23 what I told the jury was really the 1950s, with
24 Wynder-Graham and the epidemiological studies,
25 there really was a concentration of scientists

N. Benowitz - X 1 looking at the issue systematically? MR. THOMAS: Your Honor --THE WITNESS: That is when the first articles about smoking and lung cancer came out 5 in the '50s. 6 BY MR. COFER: 7 Q. Okay. Pharmacological active. Is that 8 different than psychoactive? 9 A. Psychoactive is just one type of 10 pharmacologic activity. 11 Q. Now, the fact that something is 12 pharmacologically active, doesn't necessarily mean 13 it is addictive, right? 14 A. Yes. 15 Q. Now, it is true, Dr. Benowitz, that it 16 has been known by scientists since the 1950s that 17 nicotine can change EEG or brain waves? 18 Yes. Yesterday you were telling us some 19 Q. 20 journals that were particularly well regarded. 21 Do you recall that? 22 A. Yes. 23 Q. You mentioned New England Journal of 24 Medicine? 25 Α. Yes.

- Q. You mentioned the Journal of the American 2 Medical Association?
  - Α. Yes.

3

- You mentioned Lancet? Q.
- 5 Α. Yes.
- 6 Are you aware, Doctor, that as early as 7 1921, there was an article in Lancet saying that nicotine had both stimulating properties and 8 sedating properties? What was that paradox,
- Nesmith's (ph) Paradox? 10
- 11 I think it was Nesmith's Paradox. Actually, I've forgotten if that was based on that 12 13 1921 paper, but there was a paradox that was 14 discussed for many years about how could one drug 15 both stimulate you and relax you.
- 16 Right. And I guess the point I'm trying 17 to make is it's fair to say, isn't it, that it has 18 been noted for a long time in the scientific community that nicotine has these characteristics, 19 20 they can sedative, they can be stimulating, they 21 can change the brain waves of smokers, correct?
- 22 A. Yes.
- 23 Q. Okay. Let's talk a little bit about pH 24 in free nicotine. That's something you discussed 25 earlier in your testimony, correct, Doctor?

- N. Benowitz X
- A. Yes.

3

6 7

- Q. And basically what I understood you to say is that the pH, and that's that acid versus alkalinity aspect of the environment surrounding nicotine can influence how much nicotine is bound and how much is unbound or free, right?
  - A. Yes.
- Q. And again, that's been known since at least 1929, right?
- 10 A. I forget whether it was 1929, but it has 11 been known for some time.
- 12 Q. Lots of articles about that in the 13 scientific literature in the '70s?
  - A. Yes.
- 15 Q. Are you familiar with the Tobacco Working 16 Group?
- 17 A. I am not sure. You will have to refresh 18 my memory.
- 19 Q. Tobacco Working Group, a combination of 20 public health officials, Ernst Wynder and others; 21 people from the National Cancer Institute.
- 22 A. Yes.
- Q. People from the cigarette companies, including Philip Morris, working together to see
- 25 if they could develop a less-hazardous cigarette,

```
N. Benowitz - X
1 right?
        Α.
3
        Q.
            Are you aware in 1976, the Tobacco
    Working Group actually recommended the companies
    consider developing cigarettes with more free
 6
    nicotine?
7
        Α.
            Yes.
8
        Q. The thinking was that if it was the tar
9
    that caused, caused the health problems, and
    nicotine was a fundamental reason people smoked,
10
11
    that if you could find a way to reduce the tar and
12
    keep enough nicotine, then smokers would get the
13
    satisfaction they wanted, that might be a
14
    responsible approach to the smoking health
15
    problem, correct?
16
        Α.
17
        Q. There was a document that Mr. Thomas
18 showed you that talked about impact. Remember
19
    that?
20
        Α.
             Yes.
21
        Q. And there was discussion about what
22
    impact really means in cigarettes, correct,
23
   Doctor?
```

Q. Impact is a term that refers to what the

24

25

Α.

- N. Benowitz X
- smoke feels like in the back of the mouth or throat, right?
  - A. Yes

- Q. Another word for impact is something that is called throat scratch?
- 6 A. Yes. It is similar. It is a similar 7 concept.
- 8 Q. And for whatever reason, it appears that 9 a lot of people prefer cigarettes that have impact 10 or throat scratch, right?
- 11 A. Yes.
- Q. Let's talk just a little bit about
  definitions of addiction. Yesterday, I think one
  of the first things that you told the jury was
  your definition of addiction was compulsive use of
  a psychoactive drug that is reinforcing. Is that
  correct, sir?
- 18 A. Yes.
- 19 Q. And you said that that definition is 20 consistent with the Surgeon General's definition, 21 right?
- 22 A. Yes.
- Q. Let's see if we can kind of summarize these concepts because I know there was a lot of discussion yesterday. Addiction doesn't have a

- 1 set scientific meaning, right?
- A. Well, there have been changes in what 3 different people have meant by addiction over the years, that's correct.
- 5 Q. And that's a better way of putting it and 6 I thank you for that.

7 In a scientific way, in 1964, when the 8 Surgeon General tried to characterize cigarette 9 smoking as either a habit or an addiction, based on the definition that he applied, he said the 10 11 product is habit forming and not addictive, right? 12

- Α. That's correct.
- 13 Q. And that was because the definition he 14 used at the time required intoxication?
- 15 A. Yes.
  - Q. Severe withdrawal?
- 17 Α. Yes.

- 18 And basically antisocial behavior, right? Q.
- 19 Α. Yes.
- Now, there were others, including the 20 Ο. 21 World Health Organization, that thought there
- should be a different definition, right? 22
- 23 A. Yes.
- 24 Was in fact, was it in '64 that the World
- 25 Health Organization basically shifted from the

3

5

6

14

15

16

1 term addiction to the term dependence?

- Α.
- Q. And really was the precursor for the definition the Surgeon General ultimately adopted for addiction in 1988; is that right?
  - A. That's correct.
- 7 Q. So what we've had basically is different uses of the word addiction to describe really 8 9 different standards of proof; is that fair? Or maybe standards of proof isn't right, but the word 10 11 addiction even in the scientific community has 12 been used different ways by different people over 13 the last 30 years?
  - Α. Yes.
- So if you ask somebody, "Do you think Q. this is addictive, " you really need to know what 17 definition they're using, correct?
- 18 A. Depends on how they're asking. If you're 19 asking it in a scientific sense, yes, that is 20 correct.
- 21 Q. Okay. And that is a very good point and 22 that's a nice segue. The word "addiction" also is 23 used in an unscientific way, isn't it?
- It is used to describe behavior, loss of 24 25 control over drug use, or other behaviors, but

6

7

8

9

10

11

12

13

14 15

16

17

18

- drug addiction is used and understood to have to do with loss of control over drug use.
  - Q. And in terms of whether -- and you did go through a discussion, I think, with Mr. Thomas where you said -- and correct me if I misstate it, basically it is not whether you called it addiction or whether you call it dependence or whether you call it habit, what is important is the effect on behavior; is that fair?
  - A. That's correct.
  - Q. Now, the other -- but you did point out, some people when they use the word addiction, it takes on a negative or a moral connotation, right?
  - A. Yes. That was more so in the past than today, but that is correct.
  - Q. Because what would happen if you'd think of heroin addicts or alcoholics with delirium tremens or whatever, but you had negative social implications, right?
- 20 A. That's correct.
- Q. And it's fair, isn't it, to some extent that whole word addiction has been politicized?
- 23 A. I am not sure what you mean by 24 politicized.
- Q. Let me give you examples. If you really

N. Benowitz - X

believed cigarette smoking is a bad thing, if you called the use of that an addiction rather than a habit, that has some moralistic overtones that it is addictive.

The underlying effect may be the same, but what you call it may make a difference in how it's perceived; is that fair?

- A. I suppose it could be, but there are other things that addiction means besides the social connotations. It also means, and the Surgeon General was responding to the strength of the compulsion to use the drug, the difficulty of quitting the drug, the neuro-chemical processes as being similar. So those are also things that go along with addiction which I think the Surgeon General is trying to stress.
- Q. I'll tell you, right now I'm not quibbling whether cigarette smoking should be called an addiction, habit or a dependence. What I am really trying to get a handle on is the word addiction, okay?
- A. Yes.
- Q. And you would agree that the word addiction had been used by some because it does have a negative or a moralistic component. Do you

N. Benowitz - X 1 agree with that?

3

5

6 7

8 9

11

- It has been, that's correct. Α.
- In another way, the word is very sloppy, because we hear people say all the time, "I'm addicted to video games, " right?
- A. Well, I think you have to separate out drug addiction from other sorts of behaviors that are called addictive behaviors.
- Q. I'll quit beating a dead horse. The 10 point is the word addiction really has so many meanings that the word itself has kind of lost its scientific precision. Would you agree with that?
- 13 A. Yes and no. I think when we deal with 14 drug addictions, then I think most people 15 understand what is meant when we talk about 16 addictions to love or whatever, I think it becomes 17 more vague.
- 18 Q. Is the preferred term now within the 19 field dependence?
- 20 A. Dependence is certainly widely used. I 21 use it.
- 22 Q. But we understand, what we're really 23 describing is, and for purposes of this case, can you quit, how hard it is to quit, what effects 24 25 does smoking have that makes it harder to quit,

### N. Benowitz - X 1 are those effects psychological, are those effects physical, and whether you call it addiction or habit, the issue is the effects and whether they make it harder or prevent people from quitting, 5 right? 6 Α. Yes. 7 Q. Now, when you told the jury this morning, that it was your professional opinion that 8 Mr. Williams was addicted to use of tobacco before 1955, you were using the definition that you gave 10 us yesterday, right? Your definition, right? 11 A. Yes. I was using the definition that has 12 13 to do with the likely difficulty in stopping the 14 use of cigarettes. 15 (Discussion between 16 counsel, off the record.) 17 MR. THOMAS: Judge, we're going to need a 18 ruling. THE COURT: All right. Counsel would you 19 20 step to chambers, please. 21 (In chambers:) 22 MR. THOMAS: I can tell you why I 23 objected. Out in the courtroom, Mr. Cofer 24 showed me a Philip Morris document we referred 25 to this morning in which Philip Morris made the

finding that a number of the available smoking cessation aids are not effective and that was a document that we discussed with Dr. Benowitz.

1 2

So then he showed me an advertisement for Nicorette gum and told me that he is going to impeach Dr. Benowitz with an advertisement for Nicorette gum, but the fact of the matters is he is trying to impeach his own people in their statements in the exhibit that is in front of the jury.

THE COURT: So what is your evidentiary objection?

MR. THOMAS: (A) not on the exhibit list, (B) improper impeachment, and (C) hearsay.

MR. COFER: Let me tell you what I was trying to do. It is plaintiff's Exhibits 140, the highlighted portion is the applicable part of the testimony.

Basically it says, quote, "Available data suggests" -- let me emphasize that, "Available data suggests that nicotine gum, patches, are only minutely effective in helping smokers quit unless combined with behavioral therapy."

The Court may remember in documents yesterday, Dr. Benowitz was asked did Philip

Morris ever tell Jesse Williams that these patches and gum that he brought that they needed other therapy, and he said, "No, I am not aware of that."

Well, we learned this morning that in 1989, Mr. Williams, in fact, was prescribed Nicorette gum. Here is the package inserts that goes with the Nicorette gum. It says, "You must really want to quit smoking, to be used together with a support program. See Page 3 for details."

Page 3, "You are more likely to quit smoking by using Nicorette by using a support program that helps you break your smoking habits. There may be support groups in your area. Call your local chapter of the American Lung Association, American Cancer Society, American Heart Association for further information," et cetera.

Here is why it is relevant. First, it need not be listed because it is an impeachable exhibit; second, the memo on 144 refers to available data.

24 THE COURT: It's hearsay.

1 2

25 MR. COFER: It is not offered for the

truth of the matter asserted.
THE COURT: You are.

 THE COURT: You are. You are wanting to cite the contents of those examples by means the Nicorette program would be successful and that is --

MR. COFER: Maybe I haven't articulated myself well. What I am trying to show is a causation link. Plaintiff is saying we should have told Mr. Williams that Nicorette gum wouldn't have done it. He needed to use Nicorette gum in combination with some sort of smoking cessation group. He does not have that information; therefore, he's was doomed to continue smoking.

THE COURT: I able not suggesting that you aren't able to prove in some admissible way what a person would have known from the product information. What I am saying is this document is hearsay for its purpose with their witness.

 $\mbox{MR. COFER: }\mbox{I can ask, I assume, the}$  witness about the success --

THE COURT: He may know that Nicorette is most successful when used with a behavior modification program. You may inquire of his knowledge. You can't impeach him with a

N. Benowitz - D document that is hearsay. It is not authenticated whatsoever. 3 you are telling me is a Nicorette ad, it is not attributed to Philip Morris, it is not part of 4 5 the original exhibits. Object sustained. MR. COFER: Thank you. 6 7 (Whereupon, the following 8 proceedings were held in 9 open court, the jury being 10 present:) 11 THE CLERK: Court is in session. THE COURT: All right, Mr. Cofer. 12 13 MR. COFER: Thank you, Your Honor. 14 BY MR. COFER: 15 Yesterday, Dr. Benowitz, you were shown Ο. 16 Plaintiff's Exhibit 144. This is the memo from Carolyn Levy to Bill Campbell, regarding smoking 17 18 cessation technology. Do you recall it, Doctor? 19 Α. Yes. 20 The highlighted portion was that which Ο. 21 was read to you, and it says, quote, "Available 22 data suggests that nicotine gum, patches, are only 23 minimally effective in helping smokers quit unless 24 combined with behavioral therapy. Do you recall 25 that, sir?

#### N. Benowitz - D A. Yes. And I think you told us this morning, and Q. 3 let me refer to Defendant's Exhibit 910. This is the chart you drew on attempts to quit. Do you recall that, Doctor? 5 6 Α. Yes. 7 You told the jury that in September of Q. 8 '89 --9 THE COURT: Mr. Cofer, you put that in 10 the jurors' line of sight. MR. COFER: I meant to turn it so they 11 12 can see it. 13 THE COURT: If you are going to do that, 14 why don't you bring it up to the next to the 15 witness. He can see it; they an see it. 16 MR. COFER: Thank you, good suggestion. 17 THE COURT: That's what they pay me for. MR. COFER: It is getting late in the 18 19 day. 20 BY MR. COFER: 21 Q. This is your list on attempts to quit, 22 and you told the jury in September '89, he was 23 prescribed Nicorette chewing gum, right? 24 A. Yes. 25 Q. That is a prescription from a physician,

- 1 correct?
  - A. It was at that time.
- Q. Is it your experience as a physician that you when you prescribe medication you give the patient instructions how to use it or tell them to read the package inserts?
  - A. Hopefully.
- Q. Do you ever prescribe Nicorette or nicotine chewing gum?
- 10 A. Yes.
- 11 Q. Do you tell your patients how to use it?
- 12 A. Yes
- 13 Q. Do you tell them to read the package
- 14 inserts?

- 15 A. Yes, I do, but unfortunately many 16 physicians don't do a very good job of doing this.
- 17 Q. Right. And you, of course, have no idea 18 what Mr. Williams' physicians told him, right?
- 19 A. That's correct.
- Q. But you are familiar with Nicorette gum as a product, right?
- 22 A. Yes.
- Q. Do the manufacturers of Nicorette gum
- 24 have package inserts where they advise the patient
- 25 that in order to quit, you must really want to?

### N. Benowitz - D A. Yes. MR. THOMAS: Objection, foundation. No 3 time -- no time period included in the question. THE COURT: Rephrase your question to 5 make it time specific, please. 6 BY MR. COFER: 7 In 1989, did the makers of Nicorette gum Q. includes package inserts that said, "You must 8 9 really want to quit smoking for Nicorette to help 10 you"? Well, to be precise about this, I don't 11 12 know exactly what the package insert said in 1989 13 compared to any other time, but that is a general 14 component of the package insert. 15 Is it also a general component of the 16 package insert, over your experience with it, to 17 instruct the patient that they're more likely to 18 stop smoking by using Nicorette with a support 19 program that helps them break the habit. MR. THOMAS: Objection, no foundation. 20 21 MR. COFER: During the time that you 22 were -- that you have been a physician, that you 23 have been dealing with people, help quit 24 smoking, that you have been familiar with 25

Nicorette gum.

N. Benowitz - D MR. THOMAS: Objection, request for a ruling. 3 THE COURT: I think his objection is 4 seeking that you make your question specific to 5 the time period where the evidence shows 6 Mr. Williams received the prescription. 7 Is that the point you're making? 8 MR. THOMAS: That's correct, Judge. 9 MR. COFER: Let's do it this way. 10 BY MR. COFER: 11 Q. Let's do it this way. You are familiar 12 with the package inserts for Nicorette, correct? 13 A. Yes, in general. I can't tell you 14 exactly what it said in 1989, but I am familiar 15 with the package insert in general. 16 Q. And you prescribe Nicorette gum on 17 occasion, correct? 18 Α. Yes. You have over the years, correct? 19 Q. Yes. 20 Α. 21 Q. Are you aware of any major changes, do

22 you recall any major changes in the package

A. No. There was a minor change when the

form of gum was added, but I don't think it's been

23 inserts?

24

3

6

7

14

15

- 1 a major change, no.
  - Q. Do you have a recollection at any time that in the package inserts the patient was instructed that they were more likely to stop smoking by using Nicorette with a support program that helps you break your smoking habit?
    - A. Yes, that has been in the package insert.
- Q. And in addition, in the package insert, isn't it true that the insert would advise the patient they can call their local chapter of the American Lung Association or the American Cancer Society or the American Heart Association for further information about those programs?
  - A. Yes.
  - Q. Are you aware, Doctor, that Portland has long had smoking cessation clinics?
- 17 A. I am familiar with the Kaiser program. 18 That's the only one I am familiar with in 19 Portland.
- Q. Thank you, Doctor. Are the you familiar with the Portland Adventist program?
- 22 A. No
- 23 MR. COFER: Your Honor, if we could take 24 about a ten-minute break, I think I could get a 25 handle on where I am and when we could wrap up.

THE COURT: Jurors, go ahead and take 1 2 your afternoon recess now. Please leave your 3 notes in court. Don't discuss the case at all. 4 Watch your step coming out of the box. 5 (Whereupon, the following 6 proceedings were held in 7 open court, out of the 8 presence of the jury:) 9 THE COURT: Counsel, Mr. Rice passed me a 10 note that some jurors made the point to him that 11 they were aware they could not discuss the case. 12 They wanted to know if that meant they could not 13 discuss the pace of the trial. I instructed him to tell the jury they cannot discuss the pace of 14 15 the trial, but forewarned. 16 Go ahead and step down, sir. 17 MR. DUMAS: Your Honor, take a few 18 seconds. I would like to submit to the Court 19 the defendant's request for cautionary jury 20 instructions on the various items that we've 21 talked about regarding, number one deals with

pre-September 1988 conduct; number two, deals

early next week; number three deals with

preemption; number four deals with other

with advertising, which I believe we'll get into

22

23

24

diseases; number five deals with industry documents; and number six deals with evidence of cigarettes being defective; and number seven is neutralization.

1 2

I will provide the Court with an original and one copy, and that's for counsel.

THE COURT: If you will let me know when you request these be given, then counsel can plan to be ready to discuss them.

MR. DUMAS: I guess we can talk about that, Your Honor. Some of these items we have already dealt with. It might have be appropriate -- it might have been appropriate, frankly, had I tendered these to the Court at the beginning of plaintiff's case, but frankly we were still working on them. One consideration might be to have counsel review them and perhaps we can discuss those being provided to the jury on Monday morning.

MR. THOMAS: May I make a suggestion?
THE COURT: The next time you want an instruction given, let me know on the merits.
In the meantime, you can discuss them and we'll have an opportunity to discuss them on the merits. I appreciate the work product.

MR. THOMAS: May I make a suggestion, and 1 2 that is that various lawyering efforts in this case are going on here in the courtroom, and 3 4 also in the respective offices. 5 Providing it to the lawyers in the 6 courtroom almost guarantees that it will not get 7 back into the lawyers in the office until the 8 end of the court day which creates unnecessary 9 delay, so I would request that defense counsel 10 please fax this from the office to the office, 11 so the person who everyone knows is going to 12 respond this, Mr. Coon, can begin working on it 13 so we can be prepared. 14 MR. DUMAS: I will make that phone call 15 right now, Mr. Thomas. 16 (Recess taken, 2:30 to 17 2:48 p.m.) 18 THE COURT: Are we ready for the jury? MR. COFER: We are, Your Honor. I 19 20 anticipate needing ten minutes. 21 MR. THOMAS: Could the doctor have his 22 file back? 23 MR. DUMAS: We had it for ten seconds,

MR. THOMAS: Well, you guys didn't ask

24

25

Mr. Thomas.

```
N. Benowitz - X
      for it until ten seconds ago.
             THE COURT: Mr. Thomas, he'll get it back
3
      when they're finish.
             MR. THOMAS: Judge --
 4
             THE COURT: He knows how to ask for his
5
6
      file if he needs it. He's done just fine. If
7
      he needs his file, he'll ask for it.
8
             Okay. Bring in the jury.
9
                            (Whereupon, the following
10
                            proceedings were held in
                            open court, the jury being
11
12
                           present at 2:50 p.m.:)
13
             THE COURT: Mr. Cofer.
14
             MR. COFER: Thank you.
15 BY MR. COFER:
16
            Dr. Benowitz, one more brief topic.
       Q.
17
             You talked briefly this morning about
    withdrawal. Do you remember that?
18
19
        A. Yes.
20
            I want to talk with you about the
        Q.
21
    spectrum of withdrawal, depending upon the
22
    substance, okay?
23
        A. Yes.
24
            Let's start with heroin. You would
        Ο.
25 degree, wouldn't you, that withdrawal from heroin
```

#### 53 N. Benowitz - X 1 is quite different than withdrawal from nicotine? A. 3 Q. Heroin withdrawal can require 4 hospitalization? 5 A. It doesn't usually, but it can. 6 Q. How about barbiturates? With 7 barbiturates you get abdominal cramps? 8 A. Yes. 9 Q. Hypothermia? Yes. 10 Α. Conversions? 11 Q. Yes. 12 Α. Q. Overall weakness? 13 14 A. Yes. 15 Q. Alcohol, seizures? 16 A. Yes. 17 Hallucinations? Q. 18 Α. Yes. Disorientation? 19 Q.

Tell the jury what DTs or delirium

A. That's an extreme aspect of alcohol

Yes.

A. Yes.

Q. Delirium tremens?

A.

Q.

24 tremens are.

20

21 22

23

# 54 N. Benowitz - X 1 withdrawal where people become extremely confused, they don't know where they are. They often have a high fever, sweating, may see things that aren't there. Develop shakes or tremors and often have seizures, and full blown delirium tremens can be fatal if it is not treated. 6 7 Q. And finally, let's get to nicotine withdrawal. I think you described the classic 8 9 symptoms which are irritability? 10 Yes. Α. 11 Ex-smoker, smoker trying to quit, may Q. 12 become impatient? 13 A. Yes. 14 Q. Headaches? 15 A. Yes. 16 Q. Some sleep disturbance?

20 And that's generally just not feeling Ο. 21 right or just not feeling like yourself? 22 A. That's part of it, yes. 23 MR. COFER: Thank you, Dr. Benowitz, I 24 appreciate it. 25 THE COURT: Redirect.

## N. Benowitz - ReD REDIRECT EXAMINATION 3 BY MR. THOMAS: Q. I'd like to go into a couple of things 4 5 that were brought out during your cross-examination by Mr. Cofer. 6 I would like to direct your attention, 7 8 first of all, to Exhibit 126, which is the DeNoble 9 rat study report. Do you remember that one? A. Yes. 10 And direct your attention to Exhibit 127, 11 12 and ask that you please come down to the monitor. 13 I am going to represent to you that this is a 14 letter --15 MR. COFER: I'll object to it as beyond 16 the scope. 17 THE COURT: May I see it, please. 18 (Sidebar conference 19 between Court and counsel, 20 off the record.) 21 THE COURT: Excuse us, jurors. I need to 22 take this up outside your presence. 23 (In chambers:) 24 THE COURT: State what you're about to 25 proffer, Mr. Thomas.

MR. THOMAS: All right. In summary, this is a letter directly responsive to the impeachment of Dr. Benowitz, regarding the openness versus secrecy connected with research by Philip Morris.

It is Exhibit 127, which has been demarginaliaed, from counsel to Philip Morris, in which I've got several quotes, but the bottom line is it is obvious that such report and it's reasoning to that DeNoble report, which is the foundation which has undesirable implications for smoking and health litigation, tolerance is frequently cited at one of the marks of addiction which we just finished him going through.

It is the industry's position that one of the classic criterias for addiction is tolerance and that such has not be demonstrated in the case of nicotine. While it is true that the mele, M-e-l-e, does not discuss smoking in particular or attempt to extrapolate there experimental findings beyond the laboratory, there is nevertheless the indication simply by the fact that Philip Morris doing the research that it is viewing the research as relative to

smoking behavior.

And then that it is such views and reports are clearly at variance with motions which the industry takes in regard to nicotine and smoking and that despite the author's position, the results are extremely unfavorable.

And thus research such as this strengthens the adverse indications against nicotine as an addictive drug and that it has undesirable and dangerous implications for litigation positions the industry takes.

And this will be tied up with the testimony of another witness who will come in and testify that, in fact, the specific research that is being discussed as being against the industry's position was shortly thereafter terminated and the rats were killed and it all disappeared.

MR. COFER: A couple things, first, actually the last line of questions was withdrawal, not tolerance; two completely different problems. This deals with the DeNoble lab closing. I did not touch it in my cross. I do have documents that I did not use because they didn't go into it on direct.

58 First of all, this witness has no 1 2 firsthand knowledge; second, it is beyond the scope of cross-examination. If Your Honor permits him to go into this, I would like an 4 5 opportunity to recross using the documents, but 6 as a point, the person who does have knowledge 7 of this is coming next week, Bill Farone. 8 THE COURT: I am sustaining the objection 9 as beyond the scope of direct. 10 MR. COFER: I just asked if there was another here that we were going to fight about. 11 12 Do you have it with you? MR. THOMAS: I have a document that has a 13 14 quote on a page, it's an ADI release, and it is 15 underneath one of their stamps that was produced 16 in connection with Texas litigation. I can't 17 take it out because it is on the text. 18 THE COURT: Why do you have to display it 19 to the jury?

MR. THOMAS: I'll just read it.

20

21 22

23

2425

THE COURT: Yes. The frequency of this is extremely disruptive to the jury. You have to bring it up ahead of time.

http://legacy.library.ucsf.@du/tid/dytp@5ä00/pdfndustrydocuments.ucsf.edu/docs/nrxd0001

N. Benowitz - ReD 1 (Whereupon, the following 2 proceedings were held in 3 open court, the jury being present:) 4 5 THE COURT: All right. Jurors, we resolved that issue, and we're ready to 6 7 continue. 8 Mr. Thomas. 9 MR. THOMAS: Thank you, Judge. 10 BY MR. THOMAS: 11 Q. In regard to the question in terms of the 12 politicalization of the term "addiction," this is 13 part of 162, first paragraph, news release of 14 1988. 15 MR. COFER: Thank you. 16 BY MR. THOMAS: 17 Q. And I am going to read it to the jury. 18 This is a press release from the Tobacco Institute in response to the 1988 Surgeon General's Report, 19 20 and my question to you is, first, I'll read the 21 quote and then I'll ask the question. 22 The release says, "Clearly the report 23 issued by the Surgeon General's Office today is 24 politically rather than scientifically motivated. 25 After all the Surgeon General's opposition to

N. Benowitz - ReD smoking is well known, as is his goal of a smoke-free society by the year 2,000." 3 Now, in terms of the question of addiction about being political, is there, within 5 the mainstream world academic community, among the 6 approximately 100 scientists who consulted with 7 and reviewed the 1988 Surgeon General's Report, is there controversy regarding the definition of the 8 9 word addiction, and whether or not nicotine properly belongs within it? 10 11 A. There was very little controversy. 12 don't recall any, there may have been some, but it 13 was not -- it was not questioned. Again, we made it clear in the report that the use of addiction 14 15 was to stress the strength of the compulsive use 16 of the drug, and to say that the strength is as 17 strong as alcohol and heroin and cocaine.

18

19 20

21

In fact, we went through a detailed analyses of the number of people who quit when they try to quit. The number of people who become addicted when they try to use the drug.

We analyzed a lot of different aspects of all the drugs, including nicotine, and came out with the fact that nicotine, with the exception of intoxication and life-threatening withdrawal

symptoms and antisocial behavior, those are not relevant, but in terms of everything having to do with the strength of the drug use habit or behavior or whatever you call it, the drugs were very similar.

That was the basis, and it is stated in the report why addiction was used. And the other scientists did not disagree with that.

- Q. In regard to the twin study, do you remember Mr. Cofer asked you about that?
  - A. Yes.
- Q. I will not put it on the monitor, but I'm going to represent to you that Exhibit No. 162 is a press release from the Tobacco Institute from 1974, approximately, I think, maybe two years after the book that Dunn edited got sent up to the PSU library.

And I am going to read you their interpretation of the twin report study meaning and ask you if you agree or disagree with them, sir. This is part of the press release that was sent to newspapers around the country by the Tobacco Institute of which Philip Morris was a member.

25 "As we look now at more recent findings

12

13

14

15

16

17

18

19

20

21

22

with respect to such influences on health as environment and pollution, sex and race differences, geography and genetics, it becomes obvious that the research which lies ahead will be much more significant than what has already been 6 done. Take genetics alone. Corngay" (ph), who 7 was with the Tobacco Institute, "Corngay 8 continued, quote, a receipt study of 18,000 twins 9 showed that among identical twins there was no difference in mortality even when one twin smoked 10 11 and the other did not.

"While there were higher mortality rates among the smokers in general; in other words," continuing the quote, "when genetic traits are virtually the same, the, quote, association, end quote, between smoking and mortality virtually disappears."

Going to the end of the page, "Could it be, Corngay asked, that a high AHH level, rather than cigarettes, is, in fact, responsible, thus explaining why the vast majority of smoker do not develop lung cancer.

Now, is this inconsistent or consistent of your understanding of the studies that have done with on twins in regard to the implications

3

6 7

8

9

10

11

12 13

14

15

16

17

18

19

20

1 about causation of lung cancer by smoking 2 cigarettes?

A. Well, it's complicated. That study talks about different things. The twin studies I was talking about were the ones having to do with nicotine addiction. I actually have not read that study that you talked about, and without reading it, it is hard for me to comment.

The AHH business relates to individual susceptibility for lung cancer, because only one out of ten smokers develops lung cancer, and the question is: Why don't the other nine develop it? There may well be that there is some enzyme difference.

That's what that's talking about, maybe if one twin is protected, the other twin is protected. So we know there is a big genetic factor in terms of which smokers develop lung cancer, but the basic study, I have not read that study. I can't comment on that.

Q. All right. In regard to the position that has consistently been taken by the tobacco industry, the Tobacco Institute and Philip Morris, has there been an attempt to perpetuate controversy or create controversy about the

4 5

6

7

12

13

14 15

16

17

18 19

20

21

linkage between cigarette smoking and lung cancer and the question about addiction and nicotine?

MR. COFER: Objection, beyond the scope, beyond this witness' expertise.

THE COURT: Overruled. The objection is overruled.

Go ahead.

8 THE WITNESS: I want to make sure I
9 understand the question. It sounds like there
10 were two different questions you were asking me.
11 BY MR. GAYLORD:

- Q. In regard the position taken by Philip Morris and its organization, or an organization of which it is a part, the Tobacco Institute, or the Tobacco Industry Research Council, has Philip Morris in that organization taken the consistent position that not enough is known about the connection between cigarettes and lung cancer to make a clear connection; and that, secondly, nicotine and the word addiction cannot be properly associated?
- A. Yes. The industry has stated on many occasions that there is no proof that cigarette smoking causes lung cancer.
- Q. And that's in regard to cigarettes and

1 addiction? 2 A. A

3

5

6

7

8

9

10 11

14

15

16

17

18

19

20

21

22

- A. And they have said that cigarette smoking is not addictive, and nicotine is added for flavor or present for flavor, but its not the major factor that makes people smoke cigarettes.
- Q. Is that position consistent or inconsistent with the concepts put forward to the people at the conference and contained in the book that was sent to the college library that a puff is a dose, a cigarette is unit, a pack is a container for a day's supply of nicotine?
- 12 A. It is absolutely inconsistent with that 13 idea.

MR. THOMAS: Thank you, no further questions.

THE COURT: Thank you, Doctor. You may step down.

Jurors, we're at a point where we're not going to have any more evidence today, so I am about to let you go for the week. I wanted to pass on to you some observations, so that you don't little the wrong impression.

We've been a week together now and we have finished one witness, and you might be wondering how are we possibly going to finish in four weeks a trial if everybody testifies whose name I read to you during jury selection.

1 2

Well, first of all, there are witnesses who are shorter witnesses and witnesses who are longer witnesses. It is not at all unusual at the beginning of a trial of this nature, that foundation and background purposes more time is taken with certain witnesses than others, so don't be alarmed that this witness has taken two days relative to the schedule.

Second, the list that I read off you are the full possibilities of who may testify. That does not guarantee every one of those people is going to be called, because in the course of a trial, plans change, and the lawyers don't necessarily call everyone, so don't be concerned about that.

We are, in fact, on schedule. It might not feel like it from where you sit, but we are. I want you to know that your attention and work this week has been very much appreciated. You are free to go. You'll leave your notes here.

You'll remember not to discuss the case at all with anyone, and to avoid all forms of publicity or media attention to the case and to

```
the subject. Monday morning I need you in the
 1
 2
       jury room across the hall ready to go at 9:15.
 3
       Have a good weekend. Thank you very much,
 4
       folks, good night or afternoon, I guess.
 5
                             (Whereupon, the following
 6
                             proceedings were held in
 7
                             open court, out of the
 8
                             presence of the jury at
 9
                             3:15 p.m.:)
10
              THE COURT: We have work to do and we can
11
       start right now, or if you need five minutes to
       get organized, we can do what, too. Let's take
12
13
       fine minutes so you can figure out what we can
14
       do. We're off the record.
15
                             (Recess taken.)
16
             MR. RANDLES: I believe we decided to
17
       start with the objections and the cross
18
       designations for Uydess testimony, U-y-d-e-s-s,
19
       and I will try to be brief. Can I have the
20
       Court's permission to sit?
21
              THE COURT: Yes.
22
             MR. RANDLES: If you have our chart form
23
       of objections, Your Honor.
24
             THE COURT: I do.
25
             MR. RANDLES: And these start on this the
```

edited copy, the trial says Volume 146. 1 2 THE COURT: Yes. MR. RANDLES: We tried to match them up, 4 although on occasion we were a little off, and I will explain. The first one is on the second 5 6 page, and it is just the designation of counsel. 7 MR. TAUMAN: Your Honor, do we want to 8 take these one at a time, because we have no 9 objection to this, we did not intend -- this was 10 just put on there to show that they were present 11 and represented. We are not planning on reading 12 the designation of counsel. THE COURT: All right. That makes that 13 14 moot. 15 MR. COFER: The next objection, Your 16 Honor, I am going to withdraw, which is the only 17 other one on the front page of that sheet. THE COURT: Excellent. We're making 18 19 great progress. 20 MR. RANDLES: The next one is on Page 48. 21 THE COURT: All right, I'm there. 22 MR. RANDLES: Starting on Lines 6 and 7. 23 MR. TAUMAN: Isn't that 49, or is it 48? 24 MR. RANDLES: Yes, I'm sorry, 49 pages, 25 Lines 6 and 7, although I suppose that is an

awkward place, but also then 49, 12 through 16, and the point here is just foundation and hearsay.

1 2

THE COURT: Help me out here, Mr. Tauman.
MR. TAUMAN: Well, I hope to help you out
and shorten this. It's our position that Philip
Morris was, in fact, present. And that is part
of the predicate for getting these into
evidence. They were represented. They were
present. They heard the testimony.

They made several objections that are noted in the record, and not having made such an objection that was available to them then, this did not apply to things like motions in limine in this case. Those objections are waived, so that will sort of cut down on our work.

THE COURT: Let me back up a moment. Tell me who this witness is relative to Philip Morris.

MR. TAUMAN: This is a former Philip Morris employee who is testifying, a scientist, a chemist, I believe, left their employ and is testifying in the Miami trial that is currently going on, the Engle case, as a witness for the plaintiff or plaintiffs in that case.

THE COURT: And the transcript before me 1 2 is the transcript of his trial in the Florida 3 case? 4 MR. TAUMAN: Correct. THE COURT: And Philip Morris is a party 5 6 to the Florida case? 7 MR. TAUMAN: Correct, is a party. THE COURT: And your point with regard to 8 the current objection and many others is that if 9 10 the objection was not made at the time of trial, 11 it's waived for purposes of this proceeding. 12 MR. TAUMAN: That's correct. THE COURT: And your authority for that 13 14 is? 15 MR. TAUMAN: Well, we looked and there 16 doesn't seem to be any Oregon case law. I guess 17 it is a matter of logic in the sense, if the 18 rule requires them, in order to have the 19 testimony admissible at all, requires that the 20 adverse party be present and participating and 21 have a similar motivation to proceed. 22 And I don't think any of those issues 23 have been raised. It is a matter of judicial 24 efficiency that these objections should be 25 raised. There are situations where had they

been raised -- had they been raised and decided, for instance, some of these are lack of foundation, had they been raised at the time, then the questioner could have provided the foundation at the time.

1 2

So I have to say we did look under the Oregon hearsay rule, this is a former testimony rule, and found no authority on this point. And I believe we did not pursue the federal rule where often there is case authority on these issues.

THE COURT: Okay. Mr. Randles.

MR. RANDLES: Your Honor, there is a very good reason why there is no authority for this principle, because this principle is inapplicable. Keeping in mind the different context when these trials happen, you'll see why there shouldn't be this rule of, "Well, if it came in in one case, it has got to come in in another."

There are different rules under which the testimony is taken from state to state. We talked about that. One example that doesn't apply to this is a fine example, is the Oregon rule about learned treatises, and I suspect

we'll run into that in some of this testimony.

The second issue of importance,
Your Honor, is different motions in limine
decided. Many of these issues may well have
been resolved by Judge Kaye by motions in
limine, and that's why specific objections were
not raised in the testimony.

1 2

We don't know that, and, frankly, the purpose in offering prior testimony is to expedite proceedings, not to have to reinvestigate all of the evidentiary findings in prior proceedings.

Third, Your Honor, there are different bench conferences. We have no way to tell how many of these issues were resolved in bench conferences and in chambers, as many of the issues are in this case. My hearsay objection is not that the testimony is hearsay. My objection is to the testimony which is within itself containing hearsay, Your Honor.

THE COURT: I think I need to take up every objection on the proffer as though the witness was testifying here live, and so I have to evaluate the objection in the form presented against the purpose for which the evidence is

offered and simply make a call. 1 2 I don't think the fact that that objection did not happen to be made of record, 4 precludes the objection being made at this proceeding, so let's address the merits of the 5 6 foundation objection on Page 49. 7 MR. TAUMAN: Well, I guess the easy way 8 to do it is that this was a witness who was in a 9 position to know the information that he was 10 testifying to -- I am not sure how the term 11 foundation is being used when there is no 12 foundation for his expertise or no foundation 13 that he was in a position to hear the statements 14 that were being made. 15 But all I can say is that he was there. 16 He was part of the research team that he talked 17 about. The worked at the overall division where 18 the man that he is referring to, Mr. Osvene, 19 O-s-v-e-n-e, worked. And of course, they can 20 always bring Dr. Osvene in to testify. 21 THE COURT: Let me read the answer. 22 (Pause in proceedings.) 23 THE COURT: Anything else, Mr. Randles. 24 MR. RANDLES: Your Honor, it is correct 25 he was a researcher at Philip Morris. I have

not objected to any of the testimony that he has about his own research, and that is matters about which he has personal knowledge.

I believe he testified there were several hundred people who worked at that Philip Morris department at that time. These are questions about INBIFO. This particular witness, as is indicated, had no personal dealings with INBIFO, and he's passing along second and third hand information.

There will be testimony in this case from folks that the plaintiff's bring in or we'll designate, folks that would have first hand knowledge about this subject. This is just not one of them.

THE COURT: The objection is overruled. The answer is generally responsive to the question.

Your next objection is on Page 51, Lines 3 to 13.

MR. RANDLES: I assume the same ruling would apply, Your Honor.

THE COURT: Is this still about the same subject matter?

MR. RANDLES: Yes, it is. It is much

more detailed of him repeating things that he heard in conversations with others, but I have nothing knew to add.

1 2

 $\,$  THE COURT: The objection is overruled there.

Now, we move to Volume 147, Page 7. Relevance excluded by agreed motion in limine. Help me out here.

MR. RANDLES: Your Honor, there is a lot of discussion here about the work this fellow did for a subsequent company, that did pharmaceutical work and interaction with the Food & Drug Administration, and his views about tobacco and nicotine and whether it should be regulated by the FDA, and we have a motion in limine on that subject, and I think all of that is out

MR. TAUMAN: Your Honor, I believe that this probably is excluded by the motion in limine. I am not sure how far the motion reached, whether it's FDA regulation or just the mention of the word FDA, but this is why we're not going to argue about this.

24 THE COURT: All right. So you'll strike 25 the matter to which the objection was raised

```
1
       from your proffer?
 2
             MR. TAUMAN: Yes, Your Honor.
 3
             MR. RANDLES: That is also my next
       objection. Page 10, Lines 2 through 16, it is
 4
 5
       precisely the same objection.
             MR. TAUMAN: I'm sorry, this is on page?
 6
 7
             MR. RANDLES: Page 10, Lines 2 through
 8
       16, same objection.
 9
             MR. TAUMAN: I think it is the same
10
       issue.
11
             THE COURT: So those proffers are
12
       withdrawn by plaintiff.
             Now we're down to Page 11, Line 4,
13
14
       through Page 16, Line 18.
15
             MR. RANDLES: Yes, Your Honor, I would
       like to withdraw my objection to Page 12, Line
16
17
       18 through Page 13, Line 11.
              THE COURT: Give them a chance to absorb
18
19
       that and figure out what is in and then what
20
       their position will be.
21
             MR. TAUMAN: Wasn't that the withdrawal
22
       of the whole first part of that, the relevant
23
       lack of expertise?
24
             MR. RANDLES: Yes, I am withdrawing that.
25
             MR. TAUMAN: We're on Page 13, Line 16;
```

1 is that right? 2 MR. RANDLES: Yes, 13, Lines 16, through 3 Page 14, Line 3. It is foundation objection. 4 And I believe that the Court's prior ruling 5 probably applies. 6 THE COURT: The foundation objection is 7 overruled. 8 MR. RANDLES: Your Honor, my next two 9 objections overlap, Page 14, Lines 4 through 24, 10 they're excluded by two of the motions in 11 limine, one regarding Philip Morris' other 12 businesses, that was plaintiff's motion which we 13 agreed to, and the FDA regulation issue. 14 MR. TAUMAN: Unfortunately, I missed 15 class that day, but I'll rely on my advisor 16 here. However, I think that the FDA -- that's 17 why I was talking about whether it applies to just the mention of the FDA. They're talking 18 19 about a food regulation here and his 20 relationships --21 THE COURT: Why don't you skip the 22 material following the dashes on Line 4 down to 23 the dashes on Line 11. It looks like the matter 24 to which Mr. Randles is concerned is a 25 parenthetical.

Would that solve your problem, 1 2 Mr. Randles? The witness said, "I was asked to 3 give a presentation at one of the few talks at 4 what they call Symposium." 5 MR. RANDLES: I agree. THE COURT: And then the other material 6 7 is simply a parenthetical which doesn't seem to 8 add anything that isn't already excluded. 9 Do you degree, Mr. Tauman? 10 MR. TAUMAN: Yes, I do. THE COURT: Take that matter out. 11 MR. TAUMAN: In fairness there is a later 12 13 mention of Kraft and General Foods. The same 14 page, Line 18. 15 THE COURT: And again on Line 22. MR. RANDLES: I don't have a strong 16 17 feeling about it as long as it's not emphasized those are Philip Morris companies. I don't know 18 that it adds anything either. It can go in or 19 20 stay out, I don't care. 21 THE COURT: Just make your decision and 22 let the defense know on that. 23 Next? 24 MR. RANDLES: Your Honor, I'll withdraw 25 my next objection to Page 15, Line 15.

Page 16, Lines 2 through 18, I believe 1 2 those are covered again by the FDA issue and 3 talks about the issues I've already described. 4 THE COURT: Wait a minute. On Page 16, Line 2, the question is: "So what was your 5 next -- you quit in 1989. What was the your 6 7 next involvement with the tobacco industry?" 8 How does that relate to the FDA?" 9 MR. RANDLES: Well, the question doesn't 10 so much, but his answer, which doesn't appear 11 responsive does. He starts talking about his subsequent work in the pharmaceutical industry. 12 13 I don't know what if the answer relates to the 14 question. 15 THE COURT: I don't know how this passage 16 is excluded by the motion in limine regarding 17 18 MR. RANDLES: Well, Your Honor, I would 19 also raise a relevance objection since this 20 doesn't appear to have anything to do with Philip Morris. 21 22 MR. TAUMAN: I believe it is just 23 background of the occupation of the defendant 24 [sic] here, but I would like to skip over the 25 fact is that he goes on to talk about the FDA,

so I want to conserve all of our time. 1 2 THE COURT: So what are you telling me, 3 Mr. Tauman? 4 MR. TAUMAN: I am trying to make his 5 objection for him. 6 MR. RANDLES: I appreciate that. 7 THE COURT: I'm overruling the objection 8 on Page 16. 9 Now, we're going to the Page 17. 10 MR. RANDLES: Actually, Your Honor, the 11 next passage starts at Page 16, Line 24 through 18, 8, and it goes into detail about the FDA. 12 THE COURT: Apparently the Court hadn't 13 14 made a similar ruling in limine as has been the 15 case here. 16 MR. TAUMAN: In fact, it appears it is 17 just the opposite. They did move to strike it 18 and --19 THE COURT: That's what I'm saying, it 20 looks like the judge there didn't have the same 21 situation here, but I have got a stipulated 22 motion in limine, and I think that is fair. 23 This runs afoul of that. 24 So strike the material beginning at Line 25 24 on Page 16 through --

MR. RANDLES: Through 18/8, Your Honor. 1 2 THE COURT: Through 18/8. 3 MR. RANDLES: And then he continues that 4 subject on Page 18 on Lines 17 and 18. THE COURT: So it's okay for finally the 5 6 witness reader to say, "I finally met with them, talked to them." Is that what you're saying? 7 MR. RANDLES: I would strike that because 8 9 all that refers to the FDA business regarding 10 tobacco regulations. 11 MR. TAUMAN: I agree, it should rise or 12 fall and it apparently falls. THE COURT: It's out then. Page 18, 13 14 Lines 17 and 18 we have covered. Now where? 15 MR. RANDLES: Your Honor, I believe your 16 prior ruling would apply to my foundation 17 objection on Page 20, Lines 15 through 21. I 18 have nothing to add. 19 THE COURT: Next. 20 MR. RANDLES: Next would be Page 96, 21 Lines 2 through 13. I believe your ruling would 22 apply, as well as all of Page 96. 23 THE COURT: That's right. Objection 24 overruled. 25 MR. RANDLES: Your Honor, the passage on

Page 97, 2 through 14, first of all, it is going 1 2 to be very difficult for the jury to understand the way that this is chopped up, what he is even talking about, but if I may for just a moment, 5 he is referring here to a research project that 6 someone else at Philip Morris in another area 7 that he was utterly involved in was working on, and he wasn't even on the distribution as I 8 9 understand it for the memos about it and he's 10 speculating as to why that failed. He really 11 has no knowledge, no firsthand knowledge. THE COURT: I can't make that judgment on 12

13

14

15

16

17

18

19

20

21

22

23

THE COURT: I can't make that judgment on the record before me. I am afraid that is an issue that would go to weight. I can't tell if the witness does or doesn't, and that wasn't an objection that was made at the time.

That is the kind of thing one would expect to have been raised, so I can't insert a speculative conclusion on my part that he lacks expertise there.

MR. RANDLES: If I may, Your Honor, isn't the burden theirs to show the expertise of a witness in a foundation?

24 THE COURT: He is a Philip Morris 25 employee talking about matters that involves his

employment, and your argument is that he doesn't know enough about this particular subject to be offering firsthand knowledge about it, and I can't say that he does or he doesn't in the context of your objection is really one that goes do weight, as opposed to admissibility on the record before me. MR. RANDLES: Thank you, Your Honor, that

MR. RANDLES: Thank you, Your Honor, that is all my objections.

THE COURT: Do you have any on your cross designations?

MR. TAUMAN: No, we have no objections.

THE COURT: Good work. So you are going to have a reader and it's going to be read through entirely in one piece?

MR. TAUMAN: Yes. I guess we might inquire about procedure, whether we read through our entire piece and then they designated some portions of the direct testimony.

THE COURT: My suggestion is just this, just because it seems to work best, that if there are portions of direct and portions of cross that have been designated, it makes more sense by the listener to have the direct read by the person who is in the shoes of the direct

examiner, and the cross read by the person who is in the shoes of the cross-examiner regardless of who designated it.

We can't recreate the fiction any better than that. It just seems to me that that works better. Now, if you really care about which one of the question readers is reading whose designation, if either side cares, then you can each read your own designations back and forth, but it will be the fiction of the reader saying, "But this wasn't of the question of the tobacco lawyer. This was the question of the plaintiff's lawyer."

It is going to be hard enough for this jury to figure out what it is the witness is saying, but that's the difficulty with prior testimony. You work it out between yourselves. I suggest you let it fall that way, and I also suggest that you -- that the record of that reading will be a transcript in court in real time of how it was read.

You simply recite that the proffer is prior testimony of the witness in another proceeding on such and such date in Miami, Florida, and then start your proffer, and then

we won't have an exhibit that is part of the 1 2 record. It will actually be a transcript of what the jury heard. 3 MR. GAYLORD: That's agreeable. 4 MR. RANDLES: It is quite acceptable. 5 6 Here I am asking a local practice question, I 7 apologize for taking your time. Is it the 8 Court's preference that we substitute the reader 9 of the answer, or we keep the same person up 10 there? 11 THE COURT: One reader. Whoever is the 12 initial profferer brings a reader. MR. RANDLES: Thank you, Your Honor. 13 14 THE COURT: I think it is just helpful, 15 having had to sit through this and learn it myself, it is helpful to the listener that 16 17 before we start the people understand who this 18 person is, and that it is prior testimony 19 basically. 20 MR. GAYLORD: Who the original witness 21 was? 22 THE COURT: Yes. For example, if you 23 were going to be profferer of this, you'd say to 24 the jury, "At this time we're going to offer 25 prior system of John Jones, a Philip Morris

employee, who testified in a proceeding in
Miami, Florida, on such and such a date,
Mr. Tauman is going to be reading the part of
the witness, I'll be reading the part of the
direct examiner, Mr. Randles will be reading the
part of the cross-examiner, and then you just
proceed.
And maybe we'll just tell the jury that

And maybe we'll just tell the jury that it's sworn testimony in another proceeding and it is as though they were live in our proceeding.

MR. DUMAS: Just in case the Court hasn't been notified already, it is my understanding that Monday is going to be nothing but designation day.

THE COURT: My personal favorite. So when are we going to get through other objections and things.

MR. TAUMAN: I had planned -- we had some confusion about where these transcripts -- oh, okay, there is no confusion. We have the transcripts. I am going to work very hard to designate on those transcripts within the 48 hour rule by tomorrow morning as early as possible, and get them to them.

THE COURT: My question has to do with objections. We start -- I have an 8 o'clock and an 8:30 proceeding. I have the jury coming back at 9:15. You have something to start, and you have your tape. That is not going to take you until 10:30, so we need more.

MR. GAYLORD: I had calculated that Uydess plus the tape, if we choose to run the tape will take to the morning break. Maybe it won't.

THE COURT: Maybe I am underestimating the time. You could practice it, but we better have something ready for me to look at, at 8:45 Monday morning so we can fill out the morning if we need to. I want everybody here at 8:45, and as soon as I am done with the criminal matters, we can get into getting a few more ready.

Can we do Mr. Randles' trial exhibits?
MR. RANDLES: Your Honor, may I

reintroduce a legal assistant of mine, Teresa Becker, I would like her to join me.

THE COURT: Absolutely. Everyone has to work as part of a team. This is a big job.

MR. RANDLES: Your Honor, my understanding is our exhibit list begins on 501,

and my understanding is there is no objection 1 2 until we get to Exhibit No. 543. 3 MR. COON: That is correct, Your Honor. 4 Shall we --5 MR. RANDLES: And this was a matter that 6 I think we have resolved; is that right? Did we 7 provide you that -- may I address counsel directly? 8 9 MR. COON: The objection was hearsay. 10 MR. RANDLES: We did resolve the one I 11 was looking at. MR. COON: You're right. 12 MR. RANDLES: Your Honor, 543, if I may 13 14 approach. Your Honor, this is a work product 15 list. It was prepared with the assistance of counsel, I believe from the Council for Tobacco 16 17 18 This is not a matter that we would offer 19 for substantive evidence, but because of some of the issues that have arisen, this is something 20 21

that an expert would rely on and we might well wish to show the jury. But an expert with knowledge of these

24 matters would rely on it and say, "That's correct," but we might want to show some of the

22

23

25

1 samples to the jury, so that's why it is on the
2 list.
3 MR. COON: I'm not sure, if they're not

MR. COON: I'm not sure, if they're not getting it in substantively, I am not sure why they can show it to the jury. If the expert wants to say he can rely on it and there is a list out there, he can say that, but if he wants to show it to the jury, it's a hearsay.

THE COURT: Tell me, first, who prepared this document? Whose document is it, whose out of court statement is it?

MR. COON: It is the defendant's document prepared by its litigation people, and to show what they want to show concerning their CTR activities. It is prepared for advocacy purposes. I'm not even sure that an expert can rely on it, saying, "Yes, this is the sort of thing on which I normally rely."

THE COURT: Experts may rely on all manner of data, whether admissible or not.  $\mbox{MR. COON: Right.}$ 

THE COURT: An expert may rely on lawyer work product, as well as other forms of data. Whether it's admissible in this state as a hearsay objection depends upon the purpose for

which it is offered. 1 2 And I think Mr. Coon has a point, it is not being offered to show this is a compilation 4 that is an accurate summary of what it purports to be, which would be its truth, then what is it 5 6 being offered to show? 7 It seems to me it might come in in cross 8 depending upon the extent to which the expert's 9 opinion is attacked, and the door gets opened, 10 then it might come in, but right now to me it 11 seems like hearsay. Am I missing something? MR. RANDLES: Thank you, Your Honor. 12 THE COURT: Hearsay objection sustained 13

for now.

MR. RANDLES: The next document is 544.

I will withdraw that document giving your ruling regarding the FDA.

THE COURT: All right.

14

15

16

17

18

MR. RANDLES: The next document with an objection is the first of several types,
Your Honor, and if I may, I will be happy to provide it to the Court, it is the CV of one of the original scientific advisory board members or staff members of the Council for Tobacco
Research.

The first one is dated 1957, so it's an ancient document, so are several of them. These are matters that our expert will rely upon. The fundamental purpose of these, I do not anticipate, frankly, Your Honor, sending these back to the jury room unless a significant challenge is made to the qualifications of these members.

But they do go to notice. They do go to the fact that these were generally accomplished scientists. It is not being offered for truth of a particular date they went to school or the particular articles they published.

Ms. Becker has just pointed out to me that actually the date I have on my list is the date the first person began to serve and many of these are not ancient documents, they have been compiled over the years, so I withdraw that statement.

THE COURT: The objection?

MR. COON: The objection is hearsay, Your
Honor, they were created in September of '91,
most of them, as far as I know. They are
offered for their truth to show that these
scientists are qualified.

THE COURT: The witnesses may clearly 1 2 talk about the substance of the qualifications of these folks who were part of the original CTR 3 4 group. It is hearsay at this point. MR. RANDLES: Thank you, Your Honor. 5 6 That will take us down to Exhibit 589, 7 that is withdrawn. 8 MR. COON: The number again? 9 MR. RANDLES: 589. 10 The next item I believe that is an issue 11 is 593. 12 MR. COON: 591. MR. RANDLES: I didn't have a note, but 13 14 if you do, let's address those. 15 Your Honor, the first item is 590, it's 16 is a letter from Paul Hahn who was the first 17 president of Council for Tobacco Research. 18 Stanley Barnes (ph) who was the Assistant 19 Attorney General of the United States for antitrust enforcement, Tobacco Industry Research 20 21 Committee and its proposed functions. 22 It's a 1954 document, so it's an ancient 23 document, so the hearsay objection ought not 24 apply, but this document is not going to be 25 offered for the truth of the matter contained in it, it is merely offered to show notice to the Government of the creation and formation of the Tobacco Industry Research Committee.

MR. COON: I guess I have a relevance objection in the first place to that.

THE COURT: Well, it's relevant, because the plaintiff is attacking the CTR as a front and a shield and something that has a false pretense associated with it.

MR. COON: Right.

1 2

THE COURT: The defense is entitled to offer its version of the purpose for the CTR, and notice to the Government, that creating this is some evidence of that. It's relevant. That objection is overruled.

MR. COON: There is an attachment which is the statement concerning the origin and purpose, which if it is not offered for its truth, then we'll accept that it is not. I'm not sure if that covers the letter or the attachment as well.

THE COURT: He says it is not hearsay because it's an ancient document. Remember how that worked?

MR. COON: That it is. I do, Your Honor.

94 THE COURT: That's the beauty of being in 1 2 the middle, you get to see that the rules work 3 both ways. 4 So the hearsay objection is overruled, 5 because Mr. Coon concedes it is an ancient 6 document, and it is relevant for the purpose I 7 just articulated. 8 MR. COON: Expect as to hearsay contained 9 in the attachment. 10 THE COURT: The old hearsay within 11 hearsay. 12 MR. COON: Examination of all recent 13 reports and publications, however, reveals that 14 manufacturers such as various types of air 15 pollution cause cancer.

> THE COURT: Oh, Mr. Coon, that is such an innocuous statement in the context of we had so many statements already in two days worth of testimony about possible causes of cancer, do you really think that that needs to be redacted? MR. COON: That might make it cumulative, I suppose.

23 THE COURT: Take a look at it in context, 24 tell me if you want a ruling and I'll rule. Let 25 me see the documents.

16

17

18

19

20

21

22

MR. RANDLES: If I can briefly respond 1 2 and hopefully short circuit this, Your Honor. I would not be proposing to offer the attachment 3 4 either for the truth of the matter asserted 5 about what other scientists have concluded. The 6 purpose of this document is notice to the 7 Government. 8 MR. COON: And I would say if that is 9 true then the attachment is unnecessary and just 10 the letter should do it. 11 THE COURT: The entire proffer may come in, not for its truth, but to show what Philip 12 13 Morris did in terms of notifying the Government. 14 The hearsay within hearsay objection is 15 overruled. 16 Next. 17 MR. RANDLES: Your Honor, the next 18 document is the response from the Attorney 19 General of the United States essentially 20 thanking him for his letter. 21 MR. COON: In light of your ruling, we 22 preserve our objection. 23 THE COURT: That is simply offered to

show that the document was received.

MR. RANDLES: Yes, Your Honor.

24

25

THE COURT: Proceed. 1 2 MR. RANDLES: The next document with an 3 issue, I believe, is 593, which we agreed to 4 withdraw. 5 THE COURT: Thank you. 6 MR. RANDLES: The next document with an 7 issue is 594, which pursuant to the Court's ruling regarding FDA we withdraw. 8 9 The next document with an issue raises an 10 issue that will cover many of the following 11 documents, so if I may, a word of introduction, Your Honor. What this is, it is a publication 12 by Dr. Samuel Bellet, B-e-l-l-e-t, from the 13 14 scientific literature. 15 This particular one is an ancient 16 document, but I don't think I'll have to rest 17 upon that because this is not offered to prove 18 the truth of the matter contained in the 19 article. It is merely offered to show 20 researchers who were funded by the Council for 21 Tobacco Research, published the results of their 22 research in the scientific literature, and these 23 are examples of that, so it is simply to show 24 publication, not the truth of the matter. 25 THE COURT: What is the form of the

exhibit? Title of article and author? 1 MR. COON: It's the article. 2 3 MR. RANDLES: It is the article itself, 4 Your Honor. THE COURT: So this is an example of 5 6 publication by a researcher funded by CTR, of 7 that researcher's research? MR. RANDLES: Of his publication of his 8 9 research results. 10 THE COURT: You can't have the whole 11 article in and stand by in argument that you are 12 not offering it for its truth. Maybe the title and the date and prove that it was funded by 13 14 CTR. Otherwise, you are going way over the 15 probative line for the purpose for which you are 16 offering it. 17 MR. RANDLES: I appreciate that, Your Honor. Could we just offer the first pages of 18 19 these articles then, so they would have the date 20 and the name? 21 THE COURT: Let me see what it looks 22 like. 23 MR. COON: Your Honor, I think what we're 24 going to find, these are like many treatises, 25 they often have an abstract or summary of

conclusions in the beginning, so the first page may have a lot of that stuff on it.

THE COURT: Are you sure the plaintiff doesn't want evidence about numerous studies having been made all of which demonstrate statistical association between heavy cigarette smoking and mortality?

MR. COON: A great deal of this is two-sided, Your Honor, I understand that.

THE COURT: If the purpose for which the exhibit is offered is to demonstrate that money from CTR went to fund purportedly legitimate research, something other than the text of the article needs to be proffered for that.

And I would guess that plaintiffs would agree that an exhibit could be prepared with the title of the article and the name of the author and the place where it was published, in lieu of this proffer.

I think it's fair to show that if I can show that was funded by CTR, but examples of what CTR funded is relevant, because CTR is being attacked as a front and a fake and all that. It would show the kinds of work CTR paid for, but I think the 403 issue I have is that by

going into the text of the article itself you are going too far.

1 2

So I would suggest that you prepare a different kind of exhibit that summarizes by publisher, title, year and author, of those which you contend are funded by CTR and I suspect plaintiff would stipulate that those would be admissible as an alternative to this kind of proffer.

 $\mbox{MR. GAYLORD:}\mbox{ }\mbox{Do we know how many of these there are?}$ 

MR. RANDLES: Goes to 605, about 10.

THE COURT: So long as the defendant can lay a foundation that these articles were funded by CTR, I am going to allow the defendant to prove that CTR paid for research. I'm going to allow that evidence to be specific enough to show the title of the article, who the researcher was, the place, the time it was published.

I think it text of the article is over broad, and is hearsay when considered for the limited purpose that you're identifying, Mr. Randles, so I am going to -- so long as there is the foundation that CTR has funded it,

I am going to allow you to publish to the jury 1 those titles, the authors, in any fashion that is sufficient for you, but not the article 3 4 itself. MR. COON: We'll go along with that list, 5 6 Your Honor. 7 THE COURT: Now, the articles may be 8 admissible in another and in another form. I'm 9 not suggesting they're not, but for this purpose 10 that's the way we'll deal with it. 11 MR. RANDLES: Your Honor, the next place 12 where on my list we had problems began at 611. 13 Yes, you're correct. 14 Your Honor, 605, we may use for cross. 15 We will not offer for substantive evidence. 16 Your Honor, we then have the medical 17 records issue, which goes on the original list from 611 to 625. That has now been resolved by 18 19 Mr. Sirridge and Mr. Tauman, and now comprised 20 Exhibit 882 to 903 on defendant's list, and I 21 understand that those have been resolved and 22 agreed to. 23 There is an issue for 624. There is

list is 626. This is a letter from the TIRC to the Surgeon General's Advisory Board of 1963. Your Honor, this is an ancient document; it is not subject to a hearsay objection.

It is responding to a request for information by the Attorney General on the beneficial effects of tobacco. This might be helpful, if I did bring it up. TIRC responded with the information requested by the Attorney General

This is offered to prove a number of very important issues in the case: Cooperation with health officials, state of mind, notice to the scientific community and to the public about these sorts of issues, and we think it is very probative as to the activities the CTR was undertaking, and the assistance to the Surgeon General's Committee.

There will be additional evidence on this point as to reams of valuable information provided to the Surgeon General by CTR over the years.

MR. COON: Judge, it is an ancient document, but the attachment is certainly hearsay within hearsay. It's a list of

conclusions from a wide variety of secondary publications, learned treatises, if you will, I suppose, making an ascertain that each of these is a benefit of tobacco.

1 2

So it's certainly hearsay within hearsay. And I think that's what it's offered for. I am not sure why notice to the Government of these particular substantive things makes any difference.

THE COURT: If the document and attachment are offered for the purpose of showing what Philip Morris' position was to the Surgeon General about the alleged beneficial effects of tobacco for purposes of discussing that, it may be received for that purpose.

That is not its truth, which is to say, we, Philip Morris, are publicly taking the position to you, Surgeon General that the following matters ought to be occurred as possibly beneficial. It doesn't come in as substantive evidence that Hunter and Long thought it lowered blood cholesterol.

It would have to have a limiting instruction for that to stick, but they may offer it for the purpose of showing that they

were, in fact, taking these kinds of positions publicly. That happened to be one of our controversies today, in trial, when you weren't present, but the juxtaposition of what Philip Morris did privately verses what it did publicly is clearly a hotly litigated point here.

And if this is being offered to show, "We were telling the Surgeon General these are beneficial effects for purposes of making a public disclosure," I think it could come in for that purpose without it being violative of hearsay within hearsay.

But if the defense wants a limiting instruction that there is no evidence that is substantive evidence that, for example, Hunter and Long say smoking cigarettes can lower your blood cholesterol, and proffer the instruction and I'll consider it as part of the offer of the exhibit.

Next.

MR. RANDLES: Your Honor, the next document I have with an issue is 637, and this will also cover several categories with the one qualifier being some of these are ancient documents and some are not. This one happens to

be one.

This is an article that was published in the Journal of the National Cancer Institute in July of 1971. We are not offering this or other articles that fall in this category for the truth of the matter asserted. We are offering them for notice to Philip Morris, which goes to the reasonableness of Philip Morris' subsequent conducts.

This is an article that suggested that BAP, and I will use the abbreviation because I can't pronounce the chemical phrase, which is a constituit of tobacco was dangerous and should be reduced.

The evidence will show in this case that Philip Morris in response to articles like this responded with an aggressive research program to investigate the link between BAP and health, so this article is not hearsay, first, because it is an ancient document, but more fundamentally, because we are not offering it for the truth of the matter asserted, simply to show the kinds of things that were being said in the scientific community which Philip Morris acted upon.

MR. COON: First, it is an ancient

document and being a treatise, it is full of hearsay on hearsay, footnotes, cites to everything that you can imagine. It doesn't get by hearsay on that.

The question whether its true, it seems to me that without its truth, it doesn't mean anything.

THE COURT: May I see it?

1 2

action.

MR. COON: To the extent it is legible.

THE COURT: Well Philip Morris will prove
that an article was written on Date X, entitled
such and such, in which certain subjects were
pronounced about which Philip Morris then took

It doesn't need to introduce the text of the article for that purpose, and I believe the hearsay within hearsay objection is fair in that regard. There are two great a risk that the subject matter of the article will be misperceived by the jury as substantive proof of the content.

I think it's absolutely fair for Philip Morris to offer evidence about what the controversies of the day were. Again, if an exhibit that has the name of the article and

title and publication in which it appeared is 1 2 something that you would find useful to help remind the jury of what the controversy was, 3 4 that is a handy kind of tool that could come in. 5 And the content of the article itself is 6 inadmissible as hearsay within hearsay, and it 7 goes beyond the purpose for which you are 8 telling me you need to offer it, so I think 9 Philip Morris can prove through a knowledgeable 10 witness that there were concerns about BAP or 11 whatever, and here is an article, just the face sheet of an article to flag that as a reminder 12 13 to the jury that this time frame this concern 14 was being expressed and then a witness with 15 knowledge could say, "Thereafter Philip Morris 16 undertook research about that, to demonstrate 17 its reasoning," but not the text of the article 18 as proffered. 19 MR. COON: Thank you, Judge. THE COURT: This is your copy. This one 20 21 is yours. We have about 10 minutes. 22 MR. RANDLES: We're actually making a lot 23 of progress. 24 THE COURT: I know. I am trying to let

you know that's when I turn into a pumpkin.

25

MR. RANDLES: Precisely the same issue 1 2 relates to 644, Your Honor, exactly the same. 3 THE COURT: Mr. Randles is just carrying 4 the ruling to 644. Is that acceptable, 5 Mr. Coon? 6 MR. COON: Yes, Your Honor, thank you, 7 same objection. 8 THE COURT: Same ruling then. 9 MR. RANDLES: I believe the next document 10 in issue is 646. 11 MR. COON: I have 645. 12 MR. RANDLES: Your Honor, 645, if I may 13 approach, we're going to withdraw it. 14 Your Honor, 646, this is a document that 15 I would like to bring to the Court's attention. 16 Your Honor, we have already heard a bit about 17 this and we'll hear a lot more before the case 18 is over. 19 This is concerning the FTC, Federal Trade 20 Commission criteria for testing tar and nicotine 21 content of cigarettes. This document is not 22 hearsay for several reasons. First, it is a 23 public record. It's the FTC reporting on the 24 methods that it has implemented, an evaluation 25 of the methods and demonstrates the methods

which have already become a bone of contention in this case.

1 2

So it is an exception because it is a public record report. It's an ancient document, dated 1967, and it's goes to -- it will be offered for the substance of the FTC discussing its testing method and the limits of its testing method, but it also is a notice document that we want to offer for the substance as well, of the description of the testing method.

MR. COON: Unfortunately, it contains a great deal more. It contains a number of assertions about what individual smokers do, how smoking occurs, what the Cambridge filter method does and doesn't measure.

THE COURT: We have had this document in front of the jury already, haven't we?

MR. GAYLORD: That is just what I was just going to say, Your Honor. I am really concerned about this. We had a representation from Mr. Cofer in the middle of the day today that this document was in evidence without objection.

MR. RANDLES: Mr. Cofer was mistaken. I misunderstood. The document was not in

evidence, and that's the problem. 1 2 THE COURT: Look, it is not the end of the world. We will figure this out. Just calm 3 yourselves. We'll figure out first of all 4 5 should it be in evidence. And if it shouldn't be in evidence, what do we do about the fact 6 7 that it was presented at being in evidence. 8 Let's start at the beginning. 9 Mr. Coon? 10 MR. COON: Another complicating factor I 11 suppose is that there is a separate dissenting statement from the FTC chair, beginning on the 12 fourth page of that, discussing a number of 13 14 issues about this testing and that testing and 15 what works and what doesn't. THE COURT: Well, well, well. 16 17 MR. COON: The public records exception 18 is much narrower than --19 THE COURT: What number is that, please. MR. COON: 803.8. I have often been 20 frustrated by it myself. It would not, for 21 22 example, have allowed the Surgeon General's 23 Reports in. 24 Statements concerning opinion are not 25 admissible. It is really just for factual

reporting like weights and measures, or log scale reports, other very pedestrian reports.

1 2

For example, if they can test it under these procedure and came up with a long column of numbers, that might be admissible under 803.8. This is not.

THE COURT: I would really find helpful a little bit of time on this one. And I think that probably what would be useful would be, Mr. Coon, to give you an opportunity to dissect the document and analyze the objection, and we'll take 646 up again when you have done that, and I'm a little more rested.

I don't want to miss something here, and it doesn't look like we need to resolve this before Monday morning, and we'll take this one up at the first opportunity. And we'll figure out, if it is not admissible, we need to figure out what to do about the fact that at least part of it was displayed to the jury. I think just the first page was.

And as I recall, Dr. Benowitz was very familiar with it anyway, and there was just discussion about what the FTC method or the vacuum-sucking method required, and some pretty

colorful questioning, but I am not too concerned that there was something terrible that happened in the jury's presence.

1 2

If we had an error, I'm going to assume that it was just that, an error, and we need to figure out about the exhibit, but I would rather pass on this and anything of any significant substance for tonight, because I just fear we're going to make mistake, and I want to do this properly.

So if there are any summary matters that we can accomplish in a minute or two, feel free.

MR. COON: I could offer one, I think. The Court during plaintiff's exhibit discussion had deferred ruling on 28 and 88 pending our designation of the parts in them that we wanted, and I think we can resolve Exhibit 28.

I show our redacted copy to Mr. Randles, and he, I believe, preserves his objections already discussed, but has no new objections, so I believe Exhibit 28 will be admitted.

THE COURT: Did I indicate it would be?

MR. RANDLES: Yes, Your Honor.

MR. GAYLORD: It was the British trip in 1958.

THE COURT: To a lovely island in the 1 2 North Atlantic, right? 3 MR. COON: No, that was '72. THE COURT: I was just being facetious on 4 5 a Friday night. All right. The record can show 28 in its 6 redacted form is received. You are still 7 8 working on 88. 9 MR. COON: True. 10 THE COURT: We have made some progress. 11 I appreciate everybody's work this week. 8:45 12 on Monday morning. I can't guarantee that I will be finished with all the proceedings ahead 13 14 of you, but if you are here then we can get done 15 whatever else your ready to have me do, 16 including another round of reading. It is 17 probably wise that the readings come Monday 18 morning when they're rested, and at the end of 19 the day we can tell them that's all for a while, 20 I hope, because they'll get very tired of that I 21 think, but so be it. Good evening. We're off 22 the record. 23 (Court adjourned, 2-26-99, 24 Afternoon Session at 4:30 p.m.) 25

1	REPORTER'S CERTIFICATE
2	
3	I, Katie Bradford, Official Reporter of
4	the Circuit Court of the State of Oregon, Fourth
5	Judicial District, certify that I reported in
6	stenotype the oral proceedings had upon the
7	hearing of the above-entitled cause before the
8	HONORABLE ANNA J. BROWN, Circuit Judge, on
9	February 26, 1999;
10	That I have subsequently caused my
11	stenotype notes, so taken, to be reduced to
12	computer-aided transcription under my direction;
13	and that the foregoing transcript, Pages 1
14	through 112, both inclusive, constitutes a full,
15	true and accurate record of said proceedings, so
16	reported by me in stenotype as aforesaid.
17	Witness my hand and CSR Seal at Portland,
18	Oregon, this 26th day of February, 1999.
19	
20	
21	
	Katie Bradford, CSR 90-0148
22	Official Court Reporter
23	
24	I certify this original/duplicate
	original is valid only if it bears my red
25	colored CSR Seal. Katie Bradford

